The anti-infective medicine market in Türkiye has experienced substantial growth from 2013 to 2023, where it stood at 8.67 billion New Turkish Liras. This growth has been marked by varying year-on-year percentage increases, with notable spikes in 2018 (29.76%) and 2019 (34.81%). Over the last five years leading up to 2023, the compound annual growth rate (CAGR) averaged 17.34%. This indicates a robust market expansion, driven by factors such as rising healthcare awareness, improved healthcare infrastructure, and increased infection rates.
Looking forward, the forecast suggests a continued albeit decelerating growth trend with a forecasted CAGR of 6.66% from 2024 to 2028. This is expected to result in an overall growth rate of 38.05% by 2028, reaching approximately 13.27 billion New Turkish Liras. This projection reflects an anticipated stabilization in market expansion as the sector matures.
Future trends to watch for include the impact of new regulatory frameworks, advancements in biotechnology, potential health crises, and shifts in the competitive landscape. Monitoring these factors will be crucial for strategic planning and investment decisions in the anti-infective medicine market in Türkiye.
